INFECTIOUS DISEASE

8 minute read

Apr. 29, 2023

The First Dengue NS3-NS4B Inhibitor to Enter the Clinic

JNJ-1802

oral first-in-class DENV (NS3-NS4B) inhibitor Ph. I for dengue from a DENV-2 phenotypic antiviral screen Nature, March 15, 2023 Janssen, BE + FR

Drug Hunter Team

JNJ-1802, oral first-in-class DENV (NS3-NS4B) inhibitor, Ph. I for dengue from a DENV-2 phenotypic antiviral screen, Nature, March 15, 2023 JANSSEN, BE + FR

Other molecules you may be interested in